The Big Peptide Harvest Has Begun

Someone tried it to sell you peptides where? If not, they probably will soon. Once a favorite among bodybuilders and biohackers, peptides are a popular group of products promoted by both promoters and the Secretary of Health and Human Services in the US.

Earlier this year, Robert F. Kennedy Jr. told reporter Joe Rogan that the government wants to loosen restrictions on peptide production. This week, it can finally happen: On July 23 and 24, the Food and Drug Administration will discuss whether to reestablish a group of peptides so that pharmacies can legally create a traditional mixture, a process known as compounding. The move would reverse a decision made in 2023 by the Biden Administration, which prohibited certain peptides from being included.

Even the scientists working at the agency said so urged against itmany in the industry tell WIRED they believe the FDA will approve the revisions, since the committee agreed to review them. includes peptide boosters. Some players in the telehealth world are already working on the idea that the floodgates will soon open. “We’re getting everything ready,” says Myra Ahmad, CEO of telehealth platform Mochi Health, which is initially focused. GLP-1 medicine. “We have a pharmacy that has done all the safety testing, including pricing.”

Some of the biggest telehealth companies have been waiting for this moment for over a year. Virtual healthcare juggernaut Hims & Hers Health bought a peptide manufacturing facility in February 2025 and is currently developing peptide treatments, according to its chief medical officer Anant Vinjamoori, who is scheduled to testify at the FDA hearing. Joshua Fritzler, president of the pharmaceutical company Olympia Pharmaceuticals, says that the company has been preparing in advance for the expected changes, “spending a lot of money to develop these formulations” to be ready if the FDA gives the green light.

“There’s an understanding in the industry that there’s something big going on,” he says.

The development of GLP-1 encouraged people to take injections at home, and became a cash cow in pharmacies and real hospitals. Now, however, many of these companies are eager to expand their horizons. Cole Thomas, director of sales and operations at drug marketing and technology platform RxConnexion, says some of the company’s integrative clients are already testing potentially popular peptides. One of the variations, BPC-157it is referred to as a medicinal product and is half of the mixture known as the “Wolverine stack.” (BPC stands for “Body Protection Compound.”)

Cameron Bravo, a research scientist at the biotech company Sapho Bio, says his company has already been asked to test different peptides. (Mochi Health is a client.) Sapho Bio conducts tests to “validate” the forms that customers bring in, ensuring that the ingredients are not contaminated and that they are properly sealed. So far, it has been tested BPC-157, as well as unknown offerings such as MOTS-c, which are considered “exercise in a vial” by evangelists. Some of the pharmacies that the company works with are already testing several products, at a higher cost. “They’re probably putting like $100,000 into this before they get out,” he says.

Even if this week’s meeting is exactly what the peptide promoters want, the committee is agreeing to all the things that will be discussed, which will not bring the green light to the suppliers. The next phase includes a review period, during which the FDA will issue regulations and the public can comment on them. Gerard Olson, who was most recently director of research at LegitScript, a company that provides licenses to healthcare providers and pharmacies.